• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
In vitro activity of DX-619, a novel des-fluoro(6) quinolone, against a panel of Streptococcus pneumoniae mutants with characterized resistance mechanisms.新型去氟（6）喹诺酮类药物DX-619对一组具有明确耐药机制的肺炎链球菌突变株的体外活性。
Antimicrob Agents Chemother. 2006 Feb;50(2):796-8. doi: 10.1128/AAC.50.2.796-798.2006.
2
In vitro activities of DX-619 and comparison quinolones against gram-positive cocci.DX-619及对照喹诺酮类药物对革兰氏阳性球菌的体外活性
Antimicrob Agents Chemother. 2006 Jun;50(6):2255-7. doi: 10.1128/AAC.00011-06.
3
DX-619, a novel des-fluoro(6) quinolone manifesting low frequency of selection of resistant Staphylococcus aureus mutants: quinolone resistance beyond modification of type II topoisomerases.DX-619，一种新型去氟（6）喹诺酮，对耐甲氧西林金黄色葡萄球菌突变体的选择频率较低：喹诺酮耐药性超越II型拓扑异构酶修饰。
Antimicrob Agents Chemother. 2005 Dec;49(12):5051-7. doi: 10.1128/AAC.49.12.5051-5057.2005.
4
Susceptibilities of healthcare- and community-associated methicillin-resistant staphylococci to the novel des-F(6)-quinolone DX-619.医疗保健相关和社区相关的耐甲氧西林葡萄球菌对新型去F(6)-喹诺酮DX-619的敏感性。
J Antimicrob Chemother. 2007 Dec;60(6):1384-7. doi: 10.1093/jac/dkm361. Epub 2007 Sep 21.
5
Antimicrobial activity of BMS 284756, a novel des-fluoro (6) quinolone and seven fluoroquinolones against Streptococcus pneumoniae.新型去氟（6）喹诺酮类药物BMS 284756及七种氟喹诺酮类药物对肺炎链球菌的抗菌活性
Clin Microbiol Infect. 2001 Oct;7(10):572-3.
6
Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae.3-氨基吡咯烷基喹诺酮类药物DC-159a和司帕沙星对DNA回旋酶和拓扑异构酶IV的双靶点作用：对减少体外喹诺酮耐药肺炎链球菌产生的作用
J Antimicrob Chemother. 2008 Jul;62(1):98-104. doi: 10.1093/jac/dkn136. Epub 2008 Apr 4.
7
In vitro development of resistance to DX-619 and other quinolones in enterococci.肠球菌对DX - 619及其他喹诺酮类药物的体外耐药性发展
J Antimicrob Chemother. 2006 Dec;58(6):1268-73. doi: 10.1093/jac/dkl421. Epub 2006 Oct 24.
8
Quinolone resistance mechanisms in pneumococci.肺炎球菌中的喹诺酮耐药机制。
Clin Infect Dis. 2004 May 15;38 Suppl 4:S350-6. doi: 10.1086/382692.
9
In vitro activities of novel des-fluoro(6) quinolone BMS-284756 against mutants of Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus selected with different quinolones.新型去氟（6）喹诺酮BMS-284756对用不同喹诺酮类药物筛选出的肺炎链球菌、化脓性链球菌和金黄色葡萄球菌突变株的体外活性
Antimicrob Agents Chemother. 2002 Mar;46(3):934-5. doi: 10.1128/AAC.46.3.934-935.2002.
10
Activity of DX-619 compared to other agents against viridans group streptococci, Streptococcus bovis, and Cardiobacterium hominis.与其他药物相比，DX - 619对草绿色链球菌、牛链球菌和人心杆菌的活性。
Antimicrob Agents Chemother. 2006 Dec;50(12):4191-4. doi: 10.1128/AAC.01110-06. Epub 2006 Oct 16.

引用本文的文献

1
Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.多重耐药肺炎链球菌感染：当前及未来的治疗选择
Drugs. 2007;67(16):2355-82. doi: 10.2165/00003495-200767160-00005.
2
Lack of effect of DX-619, a novel des-fluoro(6)-quinolone, on glomerular filtration rate measured by serum clearance of cold iohexol.新型去氟（6）-喹诺酮DX-619对通过冷碘海醇血清清除率测定的肾小球滤过率无影响。
Antimicrob Agents Chemother. 2007 Jun;51(6):1912-7. doi: 10.1128/AAC.01223-06. Epub 2007 Mar 19.
3
Intracellular penetration and activity of DX-619 in human polymorphonuclear leukocytes.DX-619在人多形核白细胞中的细胞内渗透及活性
Antimicrob Agents Chemother. 2006 Sep;50(9):3173-4. doi: 10.1128/AAC.00427-06.

本文引用的文献

1
In vitro antibacterial activity of DX-619, a novel des-fluoro(6) quinolone.新型去氟（6）喹诺酮DX-619的体外抗菌活性
Antimicrob Agents Chemother. 2005 Jul;49(7):3040-5. doi: 10.1128/AAC.49.7.3040-3045.2005.
2
Quinolone resistance among pneumococci: therapeutic and diagnostic implications.肺炎球菌对喹诺酮类药物的耐药性：治疗与诊断意义
Clin Infect Dis. 2004 May 15;38 Suppl 4:S357-62. doi: 10.1086/382694.
3
Incidence, epidemiology, and characteristics of quinolone-nonsusceptible Streptococcus pneumoniae in Croatia.克罗地亚喹诺酮不敏感肺炎链球菌的发病率、流行病学及特征
Antimicrob Agents Chemother. 2002 Aug;46(8):2671-5. doi: 10.1128/AAC.46.8.2671-2675.2002.
4
Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000.肺炎链球菌对氟喹诺酮类药物的耐药性增加：2000年香港多中心研究结果
J Antimicrob Chemother. 2001 Nov;48(5):659-65. doi: 10.1093/jac/48.5.659.
5
Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.肺炎链球菌临床分离株中的氟喹诺酮耐药性：II型拓扑异构酶突变和外排对耐药水平的影响
Antimicrob Agents Chemother. 2000 Nov;44(11):3049-54. doi: 10.1128/AAC.44.11.3049-3054.2000.
6
Fluoroquinolone resistance in Streptococcus pneumoniae.肺炎链球菌对氟喹诺酮类药物的耐药性
N Engl J Med. 1999 Nov 11;341(20):1546-7; author reply 1547-8. doi: 10.1056/nejm199911113412013.
7
Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.加拿大肺炎链球菌对氟喹诺酮类药物的敏感性降低。加拿大细菌监测网络。
N Engl J Med. 1999 Jul 22;341(4):233-9. doi: 10.1056/NEJM199907223410403.
8
Primary targets of fluoroquinolones in Streptococcus pneumoniae.肺炎链球菌中氟喹诺酮类药物的主要作用靶点。
Antimicrob Agents Chemother. 1999 Feb;43(2):410-2. doi: 10.1128/AAC.43.2.410.
9
Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae.肺炎链球菌耐氟喹诺酮临床分离株中一种假定外排机制的流行情况。
Antimicrob Agents Chemother. 1998 Aug;42(8):2032-5. doi: 10.1128/AAC.42.8.2032.
10
Increased incidence of ciprofloxacin resistance in penicillin-resistant pneumococci in Northern Ireland.
J Antimicrob Chemother. 1998 Mar;41(3):420-1. doi: 10.1093/jac/41.3.420.

新型去氟（6）喹诺酮类药物DX-619对一组具有明确耐药机制的肺炎链球菌突变株的体外活性。

In vitro activity of DX-619, a novel des-fluoro(6) quinolone, against a panel of Streptococcus pneumoniae mutants with characterized resistance mechanisms.

作者信息

Wickman Paul A, Moland Ellen Smith, Black Jennifer A, Thomson Kenneth S

机构信息

Center for Research in Anti-Infectives and Biotechnology, Department of Medical Microbiology and Immunology, Creighton University School of Medicine, 2500 California Plaza, Omaha, NE 68178, USA.

出版信息

Antimicrob Agents Chemother. 2006 Feb;50(2):796-8. doi: 10.1128/AAC.50.2.796-798.2006.

DOI:10.1128/AAC.50.2.796-798.2006
PMID:16436749
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1366926/
Abstract

The in vitro activities of DX-619 and four other quinolones were compared against Streptococcus pneumoniae mutants that contained a variety of alterations within the quinolone resistance-determining regions. DX-619 was the most potent quinolone and was least affected by the mutations.

摘要

将DX-619及其他四种喹诺酮类药物的体外活性与肺炎链球菌突变体进行了比较，这些突变体在喹诺酮耐药决定区域内存在多种改变。DX-619是最有效的喹诺酮类药物，受这些突变的影响最小。